Peptide library / Heart & blood / Eptifibatide
Eptifibatide
A cyclic peptide platelet blocker modeled on rattlesnake venom, used in acute coronary syndromes.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Acute coronary syndromeFDA approved
- Percutaneous coronary interventionFDA approved
How it is thought to work
Eptifibatide blocks the GP IIb/IIIa receptor on platelets, preventing them from clumping together.
What the evidence shows
The PURSUIT and ESPRIT trials showed fewer heart attacks and deaths in selected patients, though newer oral antiplatelets have reduced its use.
Safety and unknowns
Bleeding and low platelet counts are the main risks.
Regulatory status
FDA-approved as Integrilin in 1998.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Heart & blood
Icatibant
FDA-approvedA ten amino acid bradykinin blocker for attacks of hereditary angioedema.
Motixafortide
FDA-approvedA CXCR4 blocker that pushes stem cells into the blood for collection before transplant.
Enlicitide
In clinical trialsAn investigational oral PCSK9 inhibitor from Merck that sharply lowers LDL cholesterol.
General information, not medical advice. Do not buy or inject unregulated peptides.